News & Articles

LifeShare Blood Center deploys Biolog-id’s cutting-edge technology providing digital visibility to convalescent plasma containing antibodies from recovered COVID-19 patients

This aims to assist labs involved with the essential RT-PCR assay part of the “test, trace and isolate” strategy

Highly specific prototype test detects the virus spike protein at clinically relevant concentrations

Our expert webinar series aims to help you get the most from your drug discovery research

Total antibody test aims to deliver superior clinical performance with 100% sensitivity and 99.8% specificity

Watch this on-demand webinar to learn about the applications for cell-based therapies and biologics using advanced high-throughput flow cytometry

The trial will study the use of ruxolitinib, a JAK inhibitor, to investigate its effect on reducing complications in deteriorating COVID-19 patients

A rare lung disease drug is being trialed to help fight COVID-19

Advance your COVID-19 research with positive and negative SARS-CoV-2 samples

The study is expected to begin enrolling in June with a target of approximately 450 patients globally

Company to make the device available through broad range of healthcare, state, employer and consumer-initiated channels

The RNAdvance Viral XP is a RNA extraction kit validated for use in infectious disease and real-time PCR virus research

Thermo Scientific Orbitrap Exploris 240 mass spectrometer drives discovery and identification with quantitative precision and accuracy to meet customers' specific analytical requirements

Dr. Ofer Sharon discusses a new cancer research platform designed to improve patient outcomes, cut costs, and minimize unnecessary adverse events

Harnessing the most powerful force in the fight against disease — natural human immunity

The first 4,000 doses have been delivered for use in the Phase 2/3 clinical trial COV002 by the University of Oxford

First patients are expected to be enrolled shortly and additional European regulatory approvals are in process

People who recovered from COVID-19 shows that most individuals had generated antibodies that were intrinsically capable of neutralizing the SARS-CoV-2 virus